Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Fineline Cube May 18, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company Deals

Sanofi to Acquire DR-0201 for $600 Million to Advance Myeloid Cell Engager

Fineline Cube Mar 21, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) announced plans to acquire DR-0201, a bispecific myeloid cell engager...

Company Deals

Kexing Biopharm and Hinova Forge Alliance to Expand Global Market Reach

Fineline Cube Mar 21, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced this week a strategic alliance with compatriot...

Company Drug

Kintor Pharmaceutical’s KX-826 Shows Promising Results in Alopecia Phase III Trial

Fineline Cube Mar 21, 2025

China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced positive topline results from the long-term safety Phase...

Company Drug

Junshi Biosciences Receives NMPA Approval for JS212 in Advanced Solid Tumors

Fineline Cube Mar 21, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced receiving clearance from the...

Company Drug

Hengrui’s Trastuzumab Rezetecan Nears 8th Breakthrough Therapy Designation

Fineline Cube Mar 21, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its trastuzumab rezetecan (SHR-A1811), an...

Company Drug

Fosun’s Henlius Receives FDA Orphan Drug Designation for HER2-Targeting HLX22

Fineline Cube Mar 20, 2025

On March 19, 2025, Fosun Pharmaceutical (SHA: 600196) announced that its subsidiary, Henlius, has received...

Company Deals

Paratek Pharmaceuticals to Acquire Optinose for $330 Million

Fineline Cube Mar 20, 2025

Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ: OPTN) announced a definitive merger agreement on March 19,...

Company Deals

Boji Medical’s Huasheng Transfers Glucosamine Sulfate Capsules Technology to Panlong

Fineline Cube Mar 20, 2025

On March 20, 2025, Boji Medical Technology Co., Ltd (known as Boji Biomedicals) (SHE: 300404)...

Company Deals

Oxford BioTherapeutics Partners with Roche on Cancer Therapeutics Discovery

Fineline Cube Mar 20, 2025

On March 19, 2025, Oxford BioTherapeutics announced a multiyear collaboration with Roche (SWX: ROG, OTCMKTS:...

Company Drug

Joyo Pharma’s JYP0035 Receives Clinical Trial Approval for Breast Cancer Treatment

Fineline Cube Mar 20, 2025

On March 14, 2025, Joyo Pharma announced that its independently developed next-generation, highly selective Class...

Policy / Regulatory

CDE Announces 92nd Batch of Reference Preparations for Generic Drug Evaluation

Fineline Cube Mar 20, 2025

China’s Center for Drug Evaluation (CDE) has released the 92nd batch of reference preparations for...

Company

HutchMed’s 2024 Financial Report Shows Dip in Revenue Amid Oncology Product Growth

Fineline Cube Mar 20, 2025

China-based HutchMed (NASDAQ: HCM, HKG: 0013) released its 2024 financial report, revealing a total revenue...

Company Deals

Servier and Black Diamond Therapeutics Ink Global Deal for BDTX-4933

Fineline Cube Mar 20, 2025

French pharmaceutical company Servier and US-based Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) announced a strategic...

Policy / Regulatory

NMPA Seeks Public Input on Drug Trial Data Protection Measures

Fineline Cube Mar 20, 2025

On March 19, 2025, China’s National Medical Products Administration (NMPA) released draft measures and procedures...

Company Medical Device

Telix Pharmaceuticals Gains Brazilian Approval for Prostate Cancer Diagnostic Agent TLX591-CDx

Fineline Cube Mar 19, 2025

Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) announced receiving clearance from the Brazilian Health Regulatory Agency...

Company Deals Hospital

Distinct Healthcare Files for Hong Kong IPO to Expand Integrated Medical Services

Fineline Cube Mar 19, 2025

Shenzhen-based Distinct Healthcare Holdings Limited, a comprehensive medical service provider with integrated online and offline...

Company

Pfizer Restructures China Operations to Boost Growth and Innovation

Fineline Cube Mar 19, 2025

US-based pharmaceutical giant Pfizer Inc. (NYSE: PFE) announced a significant leadership and organizational restructuring in...

Policy / Regulatory

CDE’s 2024 Annual Drug Review Report Shows Continued Growth in Regulatory Filings

Fineline Cube Mar 19, 2025

The Center for Drug Evaluation (CDE) released its 2024 annual drug review report, highlighting continued...

Company

Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production

Fineline Cube Mar 19, 2025

China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in...

Company Deals

GE Healthcare and NVIDIA Expand Partnership to Advance Autonomous X-ray and Ultrasound Technologies

Fineline Cube Mar 19, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced an...

Posts pagination

1 … 194 195 196 … 667

Recent updates

  • BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
  • Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.